Vyro Biotherapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $900K

  • Investors
  • 2

Vyro Biotherapeutics General Information

Description

Developer of proprietary viral platforms intended to create advanced therapies for severe central nervous system diseases. The company offers genetically engineered Zika virus-based technologies including oncolytic virotherapies and virus-like particle systems for nucleic acid delivery, enabling patients with adult and pediatric CNS (Central Nervous System) tumors as well as genetic and rare neurological disorders to access targeted and scalable treatments.

Contact Information

Website
www.vyrobio.com
Formerly Known As
Vyro Bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Avenida Professor Lineu Prestes, 2242 - CIETEC - SALA 228
  • Sao Paulo, São Paulo 05508-000
  • Brazil
+55 (11)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Avenida Professor Lineu Prestes, 2242 - CIETEC - SALA 228
  • Sao Paulo, São Paulo 05508-000
  • Brazil
+55 (11)

Vyro Biotherapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vyro Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator 27-Feb-2026 $900K Completed Startup
4. Accelerator/Incubator 31-Jan-2025 Completed Startup
3. Accelerator/Incubator 12-Jul-2024 Completed Startup
2. Angel (individual) 30-Apr-2024 $900K $2.4M Completed Startup
1. Seed Round 01-Feb-2022 $1.5M $1.5M Completed Pre-Clinical Trials
To view Vyro Biotherapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Vyro Biotherapeutics Patents

Vyro Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025043010-A1 Nucleic acid compositions for the generation of a zika virus-like particle Inactive 23-Aug-2023
EP-4482862-A1 Nucleic acid compositions for delivering exogenous polynucleotides and methods of use Pending 22-Feb-2022
US-20250171802-A1 Nucleic acid compositions for delivering exogenous polynucleotides and methods of use Pending 22-Feb-2022
WO-2023164441-A1 Nucleic acid compositions for delivering exogenous polynucleotides and methods of use Inactive 22-Feb-2022
EP-4482505-A2 Oncolytic viruses and methods of use Pending 22-Feb-2022 C12N15/1135
To view Vyro Biotherapeutics’s complete patent history, request access »

Vyro Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vyro Biotherapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Brazilian Center for Research in Energy and Materials (CNPEM) Accelerator/Incubator
Vesper (Biotechnology) Accelerator/Incubator Minority
To view Vyro Biotherapeutics’s complete investors history, request access »

Vyro Biotherapeutics FAQs

  • When was Vyro Biotherapeutics founded?

    Vyro Biotherapeutics was founded in 2021.

  • Where is Vyro Biotherapeutics headquartered?

    Vyro Biotherapeutics is headquartered in Sao Paulo, Brazil.

  • What is the size of Vyro Biotherapeutics?

    Vyro Biotherapeutics has 5 total employees.

  • What industry is Vyro Biotherapeutics in?

    Vyro Biotherapeutics’s primary industry is Drug Discovery.

  • Is Vyro Biotherapeutics a private or public company?

    Vyro Biotherapeutics is a Private company.

  • What is Vyro Biotherapeutics’s current revenue?

    The current revenue for Vyro Biotherapeutics is .

  • How much funding has Vyro Biotherapeutics raised over time?

    Vyro Biotherapeutics has raised $3.5M.

  • Who are Vyro Biotherapeutics’s investors?

    Brazilian Center for Research in Energy and Materials (CNPEM) and Vesper (Biotechnology) have invested in Vyro Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process